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that the GP had referred them to another doctor for evaluation
and treatment. Most women in the UK ﬁrst discussed UI with a
GP whereas in Germany most discussed UI with a specialist. In
Spain and France about half the women ﬁrst discussed their UI
with a GP. CONCLUSIONS: GPs are involved to varying degrees
in the initial management of UI in France, Germany, Spain 
and the UK. Even in countries where women have a choice of
whether to see a GP or specialist about UI many choose to have
their ﬁrst contact with a GP.
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OBJECTIVES: Summary measures of population health (SMPH)
are used by national governments and international agencies 
for comparative purposes. Such measures have other uses, for
example, in monitoring changes in health status over time. Com-
peting approaches for calculating SMPH have been developed
using different metrics: disability-adjusted life years (DALY) and
quality-adjusted life years (QALY). This lack of standardization
in approach might produce conﬂicting results. The present study
was designed to measure disease burden in a US national popu-
lation survey (MEPS) to test both approaches. METHODS: Two
methods are compared here: ﬁrst, the health expectancy method,
computing health-adjusted life expectancy by combining health
related quality of life (HrQoL) and survival data; second, the
health gap method, measuring disease burden by combining the
losses due to premature mortality and non-fatal conditions. Both
EQ-5D social preference weights and Global Burden of Disease
disability weights are employed to assess the effect of different
scoring systems. Four disease areas were studied: diabetes,
stroke, coronary heart disease (CHD) and asthma. RESULTS:
Using the health expectancy method based on EQ-5D values, the
highest QALY loss of 3.67 years per person was associated with
CHD, followed by diabetes (1.26), stroke (1.15) and asthma
(0.57). The results based on disability weights had the same rank
order among diseases but varied in magnitude by between 1%
and 42% compared to EQ-5D estimates. Results were similar
using the health gap method. Disability-weighted estimate for
CHD was 8508 thousand DALYs, followed by diabetes (4378),
stroke (3277) and asthma (1429); EQ-5D values produced the
same rank order but variation was lower (2% to 15% lower).
CONCLUSIONS: A single metric for measuring health status in
clinical and population studies would help improve knowledge
transfer between health care decision-makers. EQ-5D has poten-
tial value as a summary measure of population health.
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OBJECTIVES: Pneumococcal (Pnc) disease represents a major
health care concern being associated with severe complications.
Scope of this study was to evaluate the budgetary impact effect
of providing vaccination with seven-valent pneumococcal 
conjugate vaccine (PCV) to newborns in Lombardy (Italy).
METHODS: Budget impact analysis was applied to the 2004
cohort of newborns of Lombardy: efﬁcacy data as number of
pneumonia and acute otitis media (AOM) cases, and consump-
tion of resources were derived from a large multicenter single-
blind clinical study (results published) of vaccinated versus
unvaccinated Italian children. Vaccinated children were adminis-
tered 3 doses of PCV at 3, 5 and 11 months of age; Pnc morbid-
ity was recorded until the 30th month of age. Economic analysis
was performed in the perspective of the third party payer, con-
sidering direct costs (vaccine doses, administration costs, drugs,
visits and hospitalisations for management of Pnc disease com-
plications); unit cost of resources (2006 values) was retrieved from
national reimbursement tariff lists and other published sources.
RESULTS: The cost of vaccination was calculated as €133/
patient; cost of pneumonia and AOM were calculated as €2258
and €31 per case. Vaccination of the whole newborns population
of Lombardy would avoid about 6700 cases of AOM and 2700
cases of pneumonia. The economic effect of vaccination would
be a net saving, ranging from €million 1.0 to 0.8 and 0.5 for
respectively 100%, 80% and 50% vaccination coverage. These
savings may be underestimated when considering the economic
effects on cases of meningitis, the extension of vaccination bene-
ﬁts after the second year of age in the vaccinated infants and the
effect of herd immunity on total population. CONCLUSION:
Our analysis suggests that the use of PCV in infants is likely to
be economically justiﬁed due to savings from pneumonia and
AOM cases averted, in the population of newborns of Lombardy.
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OBJECTIVES: Indicators to measure the quality of health care
are increasingly being developed and used both by health care
professionals and policy makers. In the context of increasing
costs related to antimicrobial use and resistance we aimed to
develop valid antibiotic prescribing quality indicators for 
ambulatory care, producible on the basis of present ESAC
(www.ua.ac.be/ESAC) data on antibiotic utilisation.
METHODS: Experts from 15 countries participating in a Euro-
pean Science Foundation workshop in September 2005 proposed
a set of 24 indicators and subsequently scored these indicators
for their relevance to controlling antimicrobial resistance, patient
health beneﬁt, prescription cost-effectiveness and public health
policy making using a scale ranging from 1 (= completely dis-
agree), over 5 (= uncertain) to 9 (= completely agree). The scores
were processed according to the UCLA-RAND appropriateness
method and each indicator was judged valid if there was con-
sensus and the median score was not within the 1–6 interval.
RESULTS: Twenty-two participants scored. Nine indicators
were rated as valid antibiotic prescribing indicators on all four
dimensions and three extra for their relevance at least to pre-
scription cost-effectiveness. The 2004 indicator values of a valid
set of 12 quality indicators of cost-effective antibiotic utilsation
are available for 28 individual countries. The most informative
indicator “total outpatient use” varied more than threefold
between the countries with the highest (33.4 DDD per 1000
inhabitants per day (DID) in Greece) and lowest (9.2 DID in
Russia) use. CONCLUSIONS: In line with the main objectives
of antimicrobial use surveillance at the European level, this
subset can be used to describe antibiotic use in ambulatory care
in order to assess the quality of antibiotic prescribing and its
cost-effectiveness. The indicator values allow individual coun-
tries to position themselves and to deﬁne their own benchmark,
